NCT03379480

Brief Summary

The aim of this study is to examine whether yoga is efficacious as an add-on treatment for negative symptoms of schizophrenia in a randomized multi-centric trial and also to examine functional brain changes associated with self-reflection after treatment with yoga.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
96

participants targeted

Target at P50-P75 for not_applicable schizophrenia

Timeline
Completed

Started Nov 2016

Typical duration for not_applicable schizophrenia

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 11, 2016

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

December 15, 2017

Completed
5 days until next milestone

First Posted

Study publicly available on registry

December 20, 2017

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2020

Completed
Last Updated

August 28, 2020

Status Verified

August 1, 2020

Enrollment Period

3.6 years

First QC Date

December 15, 2017

Last Update Submit

August 27, 2020

Conditions

Keywords

SchizophreniaYogafMRI

Outcome Measures

Primary Outcomes (1)

  • Improvement in negative symptoms in patients with schizophrenia

    Schizophrenia patients receiving yoga as add-on treatment will have significant improvement in negative symptoms after yoga therapy compared to those in the wait-list group as reflected by a greater decrease in Scale for Assessment of negative symptoms score. This scale measures negative symptoms on a 25 item, 6-point scale. Items are listed under the five domains of affective blunting, alogia, avolition/apathy, anhedonia/asociality, and attention. A higher score indicates greater severity.

    At the end of 12 weeks of yoga

Secondary Outcomes (1)

  • fMRI changes

    At the end of 12weeks

Study Arms (2)

Yoga arm

ACTIVE COMPARATOR

Patients with Schizophrenia will undergo 12 sessions of yoga. According to randomization one group of patients will start yoga immediately after recruitment ,whereas another group will go into wait list for 12 weeks after which they will also undergo Yoga treatment.

Behavioral: Yoga arm

Control arm

NO INTERVENTION

Healthy volunteers who will not receive yoga.

Interventions

Yoga armBEHAVIORAL

Yoga module developed for patients with Schizophrenia

Yoga arm

Eligibility Criteria

Age18 Years - 45 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Schizophrenia Subject
  • ICD (International Classification of Diseases) 10 diagnosis of schizophrenia
  • capacity to provide informed consent, as evaluated by the MacArthur Competence Assessment Tool for Clinical Research
  • no other current comorbid axis I diagnosis (except nicotine abuse/dependence) and no general impaired intellectual functioning
  • Healthy volunteers:
  • Males and females between 18 and 45 years
  • Capacity to provide informed consent
  • absence of past or present psychiatric illnesses including substance abuse 4) no general impaired intellectual functioning (MMSE above24)

You may not qualify if:

  • Other current comorbid axis I diagnosis (except nicotine abuse/dependence) and general impaired intellectual functioning
  • History of alcohol or substance abuse or dependence in the last 12 months (with the exception of nicotine)
  • Any Contraindication to MRI like metal implants or paramagnetic objects within the body or claustrophobia (only for patients undergoing fMRI at NIMHANS)
  • Past history of head injury resulting in loss of consciousness or neurosurgery
  • Concomitant severe medical conditions
  • Change in dose of antipsychotic medication or Electroconvulsive therapy in the past 6weeks
  • Pregnant or lactating -

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Institute of Mental Health and Neurosciences

Bangalore, Karnataka, 560029, India

Location

MeSH Terms

Conditions

Schizophrenia

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental Disorders

Study Officials

  • Naren P Rao, MD

    National Institute of Mental Health and Neuro Sciences, India

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor ,Department of Psychiatry, NIMHANS

Study Record Dates

First Submitted

December 15, 2017

First Posted

December 20, 2017

Study Start

November 11, 2016

Primary Completion

June 1, 2020

Study Completion

June 1, 2020

Last Updated

August 28, 2020

Record last verified: 2020-08

Locations